Aditxt (ADTX) Stock Price, News & Analysis

Company Overview

Aditxt, Inc. is a biotechnology company focused on technologies designed to monitor and reprogram the immune system. The company’s work is aimed at supporting precision medicine by providing detailed information about how an individual’s immune system responds to diseases, vaccines and other biological stimuli.

Aditxt’s core technology platform, AditxtScore, is designed to analyze multiple immune responses simultaneously. Potential applications include infectious disease testing, vaccine-response monitoring, autoimmune disease research and other areas where immune-system profiling may support diagnosis, treatment development or clinical decision-making.

Founded in 2017, Aditxt is headquartered in Mountain View, California. The company has also pursued additional life-sciences initiatives and collaborations intended to expand the use of immune-monitoring and diagnostic technologies. Amro Albanna, a co-founder of the company, has served as its chief executive officer.

Key Stats

• Today's Range: $0.0036 to $0.0046
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $20,139.04
• Volume: 11.83 million shs
• Average Volume: 94.48 million shs
• Market Capitalization: $3.18 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Aditxt Stock Analysis - MarketRank™

Aditxt scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Aditxt has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Aditxt has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Aditxt is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aditxt is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aditxt has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ADTX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aditxt does not currently pay a dividend.

Dividend Growth

Aditxt does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

Aditxt has a news sentiment score of -1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Aditxt this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for ADTX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added Aditxt to their MarketBeat watchlist in the last 30 days. This is a decrease of -36% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aditxt insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.01% of the stock of Aditxt is held by insiders.

Percentage Held by Institutions

15.54% of the stock of Aditxt is held by institutions.

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/30/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ADTX
• CIK: 1726711
• Web: www.aditxt.com
• Phone: 650-870-1200
• Fax: N/A
• Employees: 60
• Year Founded: 2017

Profitability

• EPS (Trailing Twelve Months): ($100,788.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$41.71 million
• Net Margins: -360,152.50%
• Pretax Margin: -367,584.03%
• Return on Equity: -374.60%
• Return on Assets: -105.93%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.06
• Quick Ratio: 0.05

Sales & Book Value

• Annual Sales: $14.34 thousand
• Price / Sales: 0.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $259.70 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 816,000
• Free Float: 816,000
• Market Cap: $3.18 thousand
• Optionable: No Data
• Beta: 1.21